特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
959701

SPK 3006:新薬の洞察と市場予測 (2030年)

SPK 3006 - Emerging Drug Insight and Market Forecast - 2030

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 50 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
SPK 3006:新薬の洞察と市場予測 (2030年)
出版日: 2020年09月08日
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

SPK 3006はポンペ病を対象とした、現在治験中の肝臓向けAAV遺伝子治療薬です。SPK 3006は肝臓から分泌される修飾酵素を生成するように設計されており、それがGAAの血漿レベルの維持やGAAに対する免疫原性の低下を通じて、筋肉組織への取り込み量を増加させるようになっています。

当レポートでは、ポンペ病の治療薬であるSPK 3006の市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2020~2030年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、資本取引の動き、今後の市場成長の可能性などを調査・考察しております。

目次

第1章 医薬品の概要

  • 製品の詳細情報
  • 作用機序
  • 用法・用量
  • 研究開発 (R&D) 活動
    • 臨床開発
    • 安全性・有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国 (7MM) の市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場参入企業

第6章 その他の新たな治療法

第7章 付録

第8章 レポート購入オプション

図表

List of Tables

  • Table 1 SPK 3006, Description
  • Table 2 SPK 3006, Clinical Trial Description
  • Table 3 SPK 3006, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of SPK 3006
  • Figure 2 Patent Details, SPK 3006
  • Figure 3 SPK 3006, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 SPK 3006, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 SPK 3006, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 SPK 3006, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0052

"SPK 3006 - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Pompe Disease in 7 Major Markets. A detailed picture of the SPK 3006 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

SPK-3006 is an investigational liver-directed AAV gene therapy for Pompe disease. SPK-3006 has been engineered to produce a modified enzyme that is secreted from the liver, which may sustain GAA plasma levels and lower immunogenicity to GAA to potentially provide greater uptake in muscle tissue. The transgene was in-licensed in 2017 from Genethon, a non-profit research and development organization dedicated to the development of gene therapies for orphan genetic diseases from research to clinical validation. Spark Therapeutics retains global commercialization rights to SPK-3006.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around SPK 3006.
  • The report contains forecasted sales for SPK 3006 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Pompe Disease.
  • The report also features the SWOT analysis with analyst insights and key findings of SPK 3006.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SPK 3006 Analytical Perspective by DelveInsight

  • In-depth SPK 3006 Market Assessment

This report provides a detailed market assessment of SPK 3006 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • SPK 3006 Clinical Assessment

The report provides the clinical trials information of SPK 3006 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Pompe Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence SPK 3006 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Pompe Disease are giving market competition to SPK 3006 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of SPK 3006.
  • Our in-depth analysis of the forecasted sales data of SPK 3006 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SPK 3006.

Key Questions:

  • Which company is developing SPK 3006 along with the phase of the clinical study?
  • What is the technology utilized in the development of SPK 3006?
  • What is the product type, route of administration and mechanism of action of SPK 3006?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SPK 3006 development?
  • What are the key designations that have been granted to SPK 3006?
  • What is the forecasted market scenario of SPK 3006?
  • What is the history of SPK 3006 and what is its future?
  • What is the forecasted sales of SPK 3006 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to SPK 3006?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.